Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

[IH Geek [Dave]]

This board was closed to posting as part of a board audit. We only allow one board per publicly traded company. This board is still available for Ligand:

https://investorshub.advfn.com/boards/board.aspx?board_id=30942

That was the most active board with the most moderators.

[dinogreeves]

[makinezmoney]

$LGND: Stocked up on November option calls


No reason why not spread the love :)



Big things coming.







GO $LGND

[jdaniels77]

THIS IS WHERE THE ACTION SHOULD BE. NOT FCKING LGNDZ... THAT IS IRRELEVANT IN THE COVID-19 TOPIC.

[makinezmoney]

$LGND: Who did you call... Ligand or Gilead ?


LIGAND.... no FDA meeting.



GILEAD.... yes FDA meeting.




Ligand supplies into Gilead... so by defacto, Ligand prospers.

[$theDDmessiah]

I just called them said different

[makinezmoney]

$LGND: No FDA meeting today..............


Its for GILEAD.


Go to the GILEAD board they will tell you.



LIGAND is GILEADs supplier.


There is a difference.

[BeamMeUpScotty]

Anyone have a link to where it says that the FDA is meeting with the company today please? I’d be very grateful

[$theDDmessiah]

I’m buying the Rights to this company boooooom LGNYZ

[whytestocks]

News: $LGND Ligand Partner Seelos Therapeutics Becomes a Public Company

Proceeds from financing completed simultaneously with reverse merger to be used to fund pipeline which includes programs licensed from Ligand Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced that it has closed a reverse me...

Got this from https://marketwirenews.com/news-releases/ligand-partner-seelos-therapeutics-becomes-a-public-company-7551148.html

[rosemountbomber]

AF came to the defense of the company after the market closed I believe. Don't have his tweet handy.

[mr green239]

Pipe dream!?

Price: $100 - Target: $35!

citronresearch.com/wp-content/uploads/2019/01/The-Smoking-Gun-on-Ligand-Pharmaceuticals.pdf

[grow fast]

VistaTrades issued a BUY signal for (LGND) on 4.17.17

[north40000]

http://finance.yahoo.com/news/phase-3-head-head-trial-140000117.html

3% royalty LGND???

[$Pistol Pete$]

$LGND Daily and Weekly Charts

[$Pistol Pete$]

$LGND Daily Chart

[stocktrademan]

$LGND recent news/filings

bullish 106.21

## source: finance.yahoo.com

Tue, 08 Dec 2015 18:17:34 GMT ~ LIGAND PHARMACEUTICALS INC Financials


read full: http://finance.yahoo.com/q/is?s=lgnd
*********************************************************

Tue, 08 Dec 2015 15:30:00 GMT ~ VKTX: Additional Preclinical Data Shows Robust and Durable Weight Gain for VK5211-Treated Primates


read full: http://finance.yahoo.com/news/vktx-additional-preclinical-data-shows-153000687.html
*********************************************************

Tue, 08 Dec 2015 12:47:10 GMT ~ RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs

[at noodls] - PAOLI, Pa. & SAN DIEGO-- RODES, Inc. and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announce the signing of exclusive global license and supply agreements for three Captisol-enabled™ (CE) programs. ...

read full: http://www.noodls.com/view/A04630590BEAE88AA3B7EC0F26B14838F2E6233D
*********************************************************

Tue, 08 Dec 2015 12:30:00 GMT ~ RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs

[Business Wire] - RODES, Inc. and Ligand Pharmaceuticals Incorporated announce the signing of exclusive global license and supply agreements for three Captisol-enabled™ programs. Under the terms of the agreements, for each program Ligand will be eligible to receive development and commercial milestone payments, revenue from the sales of Captisol®, and royalties of 8% to 11% on future net sales.

read full: http://finance.yahoo.com/news/rodes-signs-exclusive-captisol-licensing-123000243.html
*********************************************************

Thu, 03 Dec 2015 16:13:05 GMT ~ Ligand Pharmaceuticals, Inc. Earnings Q3, 2015


read full: http://www.capitalcube.com/blog/index.php/ligand-pharmaceuticals-inc-earnings-q3-2015/
*********************************************************

$LGND charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$LGND company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/LGND/company-info
Ticker: $LGND
OTC Market Place: Not Available
CIK code: 0000886163
Company name: Ligand Pharmaceuticals Incorporated
Company website: http://www.ligand.com
Incorporated In: DE, USA

Business Description: Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.

$LGND share structure

## source: otcmarkets.com

Market Value: $2,077,060,597 a/o Dec 14, 2015
Shares Outstanding: 19,925,754 a/o Nov 07, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$LGND extra dd links

Company name: Ligand Pharmaceuticals Incorporated
Company website: http://www.ligand.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/LGND/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/LGND/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=LGND+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=LGND+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=LGND+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/news - http://finance.yahoo.com/q/h?s=LGND+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/LGND/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/LGND/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/LGND/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/LGND/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=LGND+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/LGND
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ligand+Pharmaceuticals+Incorporated&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ligand+Pharmaceuticals+Incorporated
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ligand+Pharmaceuticals+Incorporated&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.ligand.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.ligand.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.ligand.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/LGND/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/LGND
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/LGND/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/LGND/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/LGND/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000886163&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/LGND/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/LGND/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=LGND&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=LGND
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=LGND+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=LGND+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=LGND
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=LGND
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=LGND+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/LGND/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=LGND+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/LGND.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=LGND
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/LGND/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/LGND/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/LGND/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/LGND
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/LGND
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/LGND:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=LGND
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=LGND



$LGND DD Notes ~ http://www.ddnotesmaker.com/LGND

[TREND1]

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2015, and provided an operating forecast and program updates.

Financial highlights for the second quarter of 2015 include:
• Total revenues were $18.4 million and royalty revenues were $6.6 million, an increase of 74% and 26%, respectively, compared with the second quarter of 2014.
• Adjusted EPS was $1.81 and GAAP EPS was $1.11.
• The company generated operating cash of $17.6 million, a significant increase over $6.6 million of operating cash generated in the second quarter of 2014.

[TREND1]

LGND and SNY agreement

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a global license and supply agreement with Sanofi to utilize Captisol in the development and commercialization of SAR-125844, a potent MET kinase inhibitor. Under the terms of the license, Ligand will be eligible to receive potential milestone payments, royalties on future net sales and revenue from Captisol material sales. Sanofi will be responsible for all costs related to the program.

“This represents the progression and expansion of our relationship with Sanofi as they continue to make progress on SAR-125844, a novel, selective MET kinase inhibitor,” commented John Higgins, President and Chief Executive Officer of Ligand. “Captisol continues to bring significant value to our partners’ programs and shows great promise in enabling compounds in oncology, CNS, anti-infectives and many other therapy areas.”

About Captisol®

Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella at the University of Kansas’ Higuchi Biosciences Center for specific use in drug development and formulation. This unique technology has enabled seven FDA-approved products, including Amgen’s Kyprolis®, Baxter International’s Nexterone® and Merck’s NOXAFIL IV. There are more than 30 Captisol-enabled products currently in clinical development.

About SAR-125844

SAR-125844 is a potent, selective and reversible ATP-competitive MET tyrosine kinase inhibitor for intravenous (IV) administration. SAR-125844 recently completed a first-in-human, open-label, non-randomized, single agent, Phase 1 study in advanced/refractory solid tumor patients.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, hepatitis, ventricular fibrilation, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, asthma, focal segmental glomerulosclerosis (FSGS), menopausal symptoms and osteoporosis. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Baxter International and Eli Lilly.

Forward-Looking Statements

This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. These include statements regarding clinical development of SAR-125844, possibility of commercial success, efficacy, potency, competitiveness and the strength of Ligand's product portfolio. Actual events or results may differ from our expectations. For example, there can be no assurance that SAR-125844 will progress through clinical development or receive required regulatory approvals within the expected timelines or at all, that further clinical trials will confirm any safety or other characteristics or profile, that there will be a market of any size for SAR-125844 or that SAR-125844 will be beneficial to patients or successfully marketed. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Additional information concerning these and other important risk factors affecting Ligand (including Ligand’s current reliance on revenues based on sales of Promacta® and Kyprolis®, and various risks to which Ligand’s Captisol® cyclodextrin operations are subject) can be found in Ligand's prior press releases available at www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission, available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this press release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.



View source version on businesswire.com: http://www.businesswire.com/news/home/20150730005248/en/

[TREND1]

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2015 financial results on August 4, 2015. Ligand’s CEO John Higgins, President and COO Matt Foehr and interim CFO Melanie Herman will host the conference call.


Second Quarter Earnings Call

What: Ligand conference call to discuss financial results and provide general business updates

When: Tuesday, August 4, 2015

Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)

Webcast:
Conference call and replay accessible at www.ligand.com


Conference Call: [phone] within the U.S.
[phone] outside the U.S.
Passcode: Ligand

Replay: [phone] within the U.S.
[phone] outside the U.S.
Passcode: 13614901


About Ligand Pharmaceuticals

[TREND1]

LGND 30 D W M PF FLOAT 15.49

[TREND1]

Inst % Owned = 80%

[TREND1]

FLOAT = 15.49

[Quokkie]

A beast of a stock

[stocktrademan]

$LGND recent news/filings

bullish

## source: finance.yahoo.com

Mon, 08 Jun 2015 20:50:08 GMT ~ Ligand Pharmaceuticals Reports Type II Diabetes Drug Data - Analyst Blog


read full: http://finance.yahoo.com/news/ligand-pharmaceuticals-reports-type-ii-205008529.html
*********************************************************

Mon, 08 Jun 2015 07:16:00 GMT ~ 3:16 am Ligand Pharma reports favoralble results from Phase 1b Trial with LGD-6972; plans to initiate a Phase 2 Trial


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#lgnd
*********************************************************

Sun, 07 Jun 2015 21:47:04 GMT ~ Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial

[at noodls] - Presentation at the American Diabetes Association 75th Scientific Sessions SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces results from a Phase 1b clinical trial ...

read full: http://www.noodls.com/view/21AD776992E79FFB3E62974BF7130D182BE9E81E
*********************************************************

Sun, 07 Jun 2015 21:30:00 GMT ~ Ligand Announces Favorable Results From Phase 1b Trial With LGD-6972 in Type 2 Diabetes and Plans to Initiate a Phase 2 Trial

[Business Wire] - Ligand Pharmaceuticals Incorporated announces results from a Phase 1b clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus.

read full: http://finance.yahoo.com/news/ligand-announces-favorable-results-phase-213000470.html
*********************************************************

Fri, 05 Jun 2015 21:04:02 GMT ~ Ligand Announces New Time for June 7th Investor Presentation and Webcast at the American Diabetes Association 75th Scientific Sessions

[at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the start time for the previously announced investor presentation on Sunday, June 7th is now 6 p.m. Eastern ...

read full: http://www.noodls.com/view/4615FD1FB079E9F9FAB1C9CFCF64728980FD3E1E
*********************************************************

$LGND charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$LGND company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/LGND/company-info
Ticker: $LGND
OTC Market Place: Not Available
CIK code: 0000886163
Company name: Ligand Pharmaceuticals Incorporated
Company website: http://www.ligand.com
Incorporated In: DE, USA

Business Description: Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.

$LGND share structure

## source: otcmarkets.com

Market Value: $1,827,040,889 a/o Jun 09, 2015
Shares Outstanding: 19,666,748 a/o May 01, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$LGND extra dd links

Company name: Ligand Pharmaceuticals Incorporated
Company website: http://www.ligand.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/LGND/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/LGND/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=LGND+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=LGND+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=LGND+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/news - http://finance.yahoo.com/q/h?s=LGND+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/LGND/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/LGND/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/LGND/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/LGND/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=LGND+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/LGND
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ligand+Pharmaceuticals+Incorporated&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ligand+Pharmaceuticals+Incorporated
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ligand+Pharmaceuticals+Incorporated&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.ligand.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.ligand.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.ligand.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/LGND/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/LGND
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/LGND/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/LGND/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/LGND/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000886163&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/LGND/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/LGND/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=LGND&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=LGND
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=LGND+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=LGND+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=LGND
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=LGND
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=LGND+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/LGND/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=LGND+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/LGND.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=LGND
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/LGND/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/LGND/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/LGND/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/LGND
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/LGND
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/LGND:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=LGND
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=LGND



$LGND DD Notes ~ http://www.ddnotesmaker.com/LGND

[MONEYMADE]

GREAT SHORT TODAY....WEEEEEEEEEEEEEEEEE!

[maytepper]

$LGND Ligand Is An Attractive Financial Growth Story With Pipeline Optionality, Says Deutsche Bank http://www.smarteranalyst.com/2014/12/02/ligand-is-an-attractive-financial-growth-story-with-pipeline-optionality-says-deutsche-bank/

[stocktrademan]

$LGND DD Notes ~ http://www.ddnotesmaker.com/LGND

bullish
bullish macd divergence
bullish cmf divergence
bullish rsi divergence
bullish bounce off long term 50% and 38.2% fib retracements
turning resistances into supports

$LGND recent news/filings

## source: finance.yahoo.com

Thu, 13 Nov 2014 21:00:01 GMT ~ Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug


read full: http://finance.yahoo.com/news/ligand-glaxo-seek-eu-nod-210001957.html
*********************************************************

Wed, 12 Nov 2014 14:33:34 GMT ~ Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag)

[at noodls] - SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a ...

read full: http://www.noodls.com/view/A59D9F4F7926D2A50013AAF1161820D992221CA2
*********************************************************

Wed, 12 Nov 2014 14:15:00 GMT ~ Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia Indication for Revolade™ (eltrombopag)

[Business Wire] - Ligand Pharmaceuticals Incorporated announced that its partner GlaxoSmithKline plc reported the submission to the European Medicines Agency of a variatio

read full: http://finance.yahoo.com/news/ligand-partner-glaxosmithkline-announces-eu-141500987.html
*********************************************************

Tue, 04 Nov 2014 00:08:29 GMT ~ 10-Q for Ligand Pharmaceuticals, Inc.


read full: http://www.companyspotlight.com/routers/headline/23055/10004/6406783?cp_code=YAH1&1415059709
*********************************************************

Fri, 31 Oct 2014 20:24:44 GMT ~ LIGAND PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/141031/lgnd10-q.html
*********************************************************


$LGND charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$LGND company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/LGND/company-info
Ticker: $LGND
OTC Market Place: Not Available
CIK code: 0000886163
Company name: Ligand Pharmaceuticals Incorporated
Company website: http://www.ligand.com
Incorporated In: DE, USA

Business Description: Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.


$LGND share structure

## source: otcmarkets.com

Market Value: $1,157,137,723 a/o Nov 14, 2014
Shares Outstanding: 20,023,148 a/o Oct 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$LGND extra dd links

Company name: Ligand Pharmaceuticals Incorporated
Company website: http://www.ligand.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/LGND/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/LGND/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=LGND+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=LGND+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=LGND+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/news - http://finance.yahoo.com/q/h?s=LGND+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/LGND/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/LGND/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/LGND/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/LGND/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/LGND/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=LGND+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/LGND
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ligand+Pharmaceuticals+Incorporated&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ligand+Pharmaceuticals+Incorporated
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ligand+Pharmaceuticals+Incorporated&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.ligand.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.ligand.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.ligand.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/LGND/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/LGND
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/LGND/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/LGND/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/LGND/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000886163&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/LGND/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/LGND/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=LGND&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=LGND
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=LGND+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=LGND+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=LGND
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=LGND
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=LGND+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/LGND/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=LGND+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/LGND.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=LGND
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/LGND/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/LGND/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/LGND/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/LGND/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/LGND
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/LGND
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/LGND:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=LGND
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=LGND



$LGND DD Notes ~ http://www.ddnotesmaker.com/LGND

[maytepper]

$LGND $GSK Roth Capital Comments On Ligand Following EMA Submission For Revolade http://www.smarteranalyst.com/2014/11/14/roth-capital-comments-on-ligand-following-ema-submission-for-revolade/

[alsoconcerned]

I was hoping the company would put out a little good news here this Friday morning for us loyal Ligand long investors.

[maytepper]

Cantor Reiterates Hold On Ligand Pharmaceuticals, Raises PT To $49 http://www.smarteranalyst.com/2014/08/20/cantor-reiterates-hold-on-ligand-pharmaceuticals-raises-pt-to-49/

[maytepper]

Roth Capital Maintains Bullish Stance On Ligand Following 2Q14 Results http://www.smarteranalyst.com/2014/08/05/roth-capital-maintains-bullish-stance-on-ligand-following-2q14-results/

[michaeldouglas]

Investment Firm in Big Short, Their Report-
http://www.valuewalk.com/2014/06/lemelson-ligand-pharmaceuticals-lgnd-no-intrinsic-value/

[maddawg2020]

SA: 100 Percent Downside

http://seekingalpha.com/article/2270903-ligand-pharmaceuticals-severe-competitive-threat-to-key-royalty-program-and-going-concern-risk-drive-100-percent-downside?app=1&uprof=25

"Revenue and profits highly concentrated in one (single-sourced) product, and essentially two royalty agreements, one of which is set to decline precipitously.

Based on recent FDA comments, Gilead’s revolutionary Sovaldi® drug will virtually eliminate demand for Promacta®, which is Ligand’s largest royalty generating asset, accounting for as much as 72 percent of.

When backing out intangibles from the balance sheet, net share-holder equity is approximately minus $4 million."

[north40000]

LGND summary from 02/11/2014:

>>> Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31, 2013, and provided an operating forecast and program updates.

Financial highlights for the fourth quarter of 2013 include (all comparisons are with the fourth quarter of 2012):

Total revenues increased 8% to $14.7 million, and royalty revenues increased 48% to $7.1 million
Non-GAAP net income per share from continuing operations was $0.35 per diluted share
Net income increased 76% to $1.9 million, or $0.09 per diluted share

A description of the non-GAAP calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table titled “Non-GAAP Financial Measures.”

“2013 was a spectacular year for Ligand, and we believe we are well positioned for continued significant growth in 2014 and beyond. Throughout 2013 the remarkable progress of several partnered programs drove major contributions to our financial results and established a strong foundation for further growth in revenues and earnings,” commented John Higgins, President and Chief Executive Officer of Ligand. “Impressive operating and financial momentum continues to define Ligand with projected growth of our lead products, the recent launch of DuaveeTM, as many as four new revenue-generating products that may be approved in 2014 and partners expected to invest more than $800 million in Ligand programs this year across a vast array of promising assets.” <<<

Long wait from my initial entry @ $6.30, now a 1100% gain/share.

[Ijoking]

IT looks like a volume is way up since earnings report.
nice stock price too...

[maddawg2020]

Great earnings and new CFO!
Any thoughts?

[SandyEggoJake]

FYI:

Followers of this board may be interested to know that a shareholder proposal has been received by Ligand for its 2014 proxy season. The details of this proposal can be found at:

SpinoffLigandRnD.com

[surf1944]

8:36AM Ligand Pharma beats by $0.06, beats on revs; guides Q4 EPS below consensus, revs below consensus (LGND) 57.95 : Reports Q3 (Sep) non-GAAP earnings of $0.12 per share, $0.06 better than the Capital IQ Consensus Estimate of $0.06; revenues rose 104.0% year/year to $13.0 mln vs the $10.8 mln consensus. Co issues downside guidance for Q4, sees non-GAAP EPS of $0.15-0.17 vs. $0.21 Capital IQ Consensus Estimate; sees Q4 revs of $11-12 mln vs. $14.2 mln Capital IQ Consensus Estimate. Royalty revenue rose 78% YoY to $5.7 mln, primarily due to higher royalties from Promacta and new royalties from Kyprolis.

[surf1944]

7:04AM GlaxoSmithKline, partner of Ligand Pharma (LGND), receives marketing authorization from the European Commission for additional Revolade (Eltrombopag) Indication as the first approved treatment for Chronic Hepatitis C-Associated Thrombocytopenia (GSK) 51.12 : Co announced today that the European Commission has granted an additional indication for Revolade (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon (IFN)-based therapy.1

[surf1944]

8:30AM Ligand announces positive preclinical data for Glucagon Program in Model of Type 1 Diabetes (LGND) 34.80 : Co announced the presentation of a poster titled "Glucagon Receptor Antagonist LGD-6972 Is Efficacious in Streptozotocin-Induced Diabetic Mice" at the 73rd Scientific Sessions of the American Diabetes Association in Chicago. The poster provides data from preclinical studies of Ligand's novel compound, LGD-6972, demonstrating significant glucose lowering activity in an animal model of type 1 diabetes.

Highlights of the presentation include:

LGD-6972 is a potent and selective antagonist of the glucagon receptor (GCGR) that has previously demonstrated activity in pre-clinical models of type 2 diabetes
LGD-6972 significantly lowered fasting and non-fasting glucose levels in a mouse model of type 1 diabetes
LGD-6972 reduced HbA1c, ketone bodies, and free fatty acids in diabetic mice
LGD-6972 had additive effects when used in combination with insulin therapy and may be useful in an insulin sparing regimen

[surf1944]

8:31AM Ligand raises ownership limit for BVF partners to 25% of shares outstanding (LGND) 32.33 : Co announced that its Board of Directors has agreed to waive certain 'poison pill' provisions to allow BVF Partners L.P., including its affiliates and associates, to increase its ownership of the Company from the previous limit of 19.99% of outstanding common stock to a new limit of 24.99%, subject to certain conditions. BVF has been Ligand's largest shareholder since the second quarter of 2011 and currently owns 17.7% of the Company's outstanding stock. BVF's acquisition of stock, if any, is expected to be made in the open market or through direct purchases from other stockholders. Ligand has been diligent in setting the terms of the waiver for the potential benefit of all shareholders of Ligand. In summary, the conditions under which BVF will be permitted to exceed the current limit of 19.99% and own up to 24.99% of Ligand's outstanding stock include the following: BVF's purchases must exceed the 19.99% threshold within nine months from the date of the agreement, or the waiver for the increased ownership limit automatically terminates.

[surf1944]

8:31AM Ligand Pharma presents preclinical data on HepDirect liver-targeting technology platform at 2013 International Liver Congress (EASL); data demonstrated that HepDirect liver targeting of active nucleosides may be an effective method to improve efficacy while reducing systemic side effects in HCV treatment (LGND) 28.04 : Co announced that data from preclinical studies evaluating Ligand's HepDirect liver-targeting technology platform will be featured in a poster presentation at the 48th Annual International Liver Congress hosted by the European Association for the Study of the Liver (EASL) in Amsterdam. The data show highly targeted liver delivery of a clinically active NS5B polymerase inhibitor utilizing the HepDirect technology platform, and demonstrated that HepDirect liver targeting of active nucleosides may be an effective method to improve efficacy while reducing systemic side effects in HCV treatment. The compound using HepDirect technology efficiently targeted the liver with greatly reduced systemic distribution in preclinical models, providing further proof-of-concept of the value and utility of the HepDirect technology platform.

[surf1944]

7:02AM Ligand Pharma signs global license agreement with Spectrum Pharmaceuticals (SPPI) for Captisol-enabled melphalan (LGND) 21.86 : Co announced the signing of global license and supply agreements with Spectrum Pharmaceuticals (SPPI) for the development and commercialization of Ligand's Captisol-enabled, propylene glycol-free melphalan. Under the terms of the license agreement, Ligand is entitled to receive a license fee and is eligible to receive more than $50 million in potential milestone payments. Ligand is also eligible to receive royalties on future net sales of Captisol-enabled melphalan.

[surf1944]

Ligand Receives $1.4 Million Milestone Payment from Retrophin, Inc.
Ligand’s Partner Preparing to Initiate a Phase 2 trial for FSGS
Press Release: Ligand Pharmaceuticals Incorporated – Mon, Feb 25, 2013 9:00 AM EST

SAN DIEGO--(BUSINESS WIRE)--
Ligand Pharmaceuticals Incorporated (LGND) announces receipt of a $1.4 million milestone payment from Retrophin, Inc. (RTRX) under the terms of a license agreement signed in February 2012 for the development and commercialization of Retrophin’s lead clinical candidate RE-021. Ligand will remit $210,000 to Bristol-Myers Squibb under the terms of a previous license agreement for RE-021. Ligand is entitled to milestones and royalties on the successful future development and commercialization of RE-021 under this agreement.
RE-021 is in development for the treatment of focal segmental glomerulosclerosis (FSGS), a rare disease that attacks the kidney’s filtering system (glomeruli), causing serious scarring, kidney degeneration and ultimately loss in kidney function. An estimated 50,000 patients in the United States suffer from FSGS, with most patients diagnosed as children or young adults. Retrophin has announced that it expects to begin enrollment in a Phase 2 clinical trial known as “FONT-3” during the first half of 2013.
“We are impressed with Retrophin’s continued business successes and look forward to the initiation of the Phase 2 trial of RE-021,” commented John Higgins, President and Chief Executive Officer of Ligand. “FSGS is an orphan disease with significant, unmet medical need and no currently approved therapies. We believe that RE-021 has a very compelling therapeutic profile and that under Retrophin’s stewardship, it has the potential to become an important treatment.”
Ligand acquired RE-021 in its acquisition of Pharmacopeia in December 2008. RE-021 was formerly known as DARA (a Dual Acting Receptor Antagonist of Angiotensin and Endothelin) and possesses two clinically validated mechanisms of action that selectively block two potent vasoconstrictor and mitogenic agents, angiotensin II and endothelin 1, at their respective receptors.
About Retrophin
Retrophin is a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable options. The company is currently focused on several catastrophic diseases that primarily affect children, including FSGS, Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin’s lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for FSGS during the first half of 2013.

[surf1944]

4:08PM Ligand Pharma initiates pivotal trial of captisol-enabled, Propylene Glycol-Free Melphalan in patients with Multiple Myeloma (LGND) 18.95 +0.57 : Co announced that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma. This multi-center trial will evaluate safety and efficacy in 60 patients, and is intended to confirm the results from an earlier Phase 2 study demonstrating that the PG-free melphalan intravenous formulation was safe and well-tolerated, and met the requirements for establishment of bioequivalence to the current commercial intravenous formulation of melphalan (Sold by GSK as Alkeran for injection). Given the robust dataset compiled to date along with the pivotal study design, Ligand believes that should this pivotal trial produce positive results, the Company will be in a position to submit a 505(b)(2) New Drug Application to the U.S. Food and Drug Administration.

[surf1944]

LGND sNDA PDUFA
Fri, November 30, 12am – Sat, December 1, 12am
Calendar
FDA Calendar

[mlkrborn]

Ligand Pharma follow-up: FDA approves new indication for PROMACTA (LGND is halted) (LGND) 16.67 : GSK announced today that the FDA has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. There are limitations to the use of PROMACTA in patients suffering from chronic hepatitis C-associated thrombocytopenia. These include:

PROMACTA should not be used in an attempt to normalize platelet counts;
PROMACTA should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon therapy or limits the ability to maintain optimal interferon-based therapy;
Safety and efficacy have not been established in combination with direct-acting antiviral agents approved for treatment of chronic hepatitis C genotype 1 infection.

[surf1944]

8:30AM Ligand Pharma to receive $2 mln milestone payment from Merck triggered by initiation of Phase 2b/3 trial of Dinaciclib; reaffirms FY12 rev guidance (Q3 lowered Q4 raised) (LGND) 15.63 : Co will receive a $2 million milestone payment from Merck (MRK), known as MSD outside the United States and Canada, under the terms of a development and license collaboration for the development of dinaciclib. This milestone payment is triggered by the initiation of a Phase 2b/3 adaptive clinical trial for dinaciclib for the treatment of patients with refractory chronic lymphocytic leukemia (CLL).

Affirming its previous revenue forecast, Ligand continues to expect full year 2012 total revenues to be ~$30 mln (consensus $30.7 mln), with revenue in the third quarter now projected to be ~$6 million, versus earlier guidance of ~$8 million (cons: $8.5 mln), and revenue in the fourth quarter now projected to be ~$13 million, versus earlier guidance of ~$11 million (cons: $10.8 mln).

[surf1944]

http://investor.ligand.com/Investors/News-and-Events/Press-Releases/default.aspx